This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/13/2021
Good morning. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to NMED's third quarter 2021 financial results and business update conference call for the fiscal quarter ended March 31st, 2021. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, Please press the pound key. Thank you. All lines have been placed on mute to prevent any background noise. Mr. Colwell, you may begin your conference.
Thank you, sir. Good day, everyone. My name is Bruce Colwell, and I am NMED's Chief Financial Officer. Welcome to NMED's third quarter 2021 financial results and business update conference call. Please note that we are, once again, all joining today from remote locations, so we appreciate your patience if we happen to encounter any unexpected technical challenges today. But before we begin, we would like to go over our disclosure statements, followed by a review of the progress of our therapeutic development and cannabinoid manufacturing programs, which will be led by our President and CEO, Eric Adams, after which I will review the financial results of operations. Following that, we will be available for a question and answer session. We also have joining us today to address your questions, Eric Hsu, Senior Vice President of Preclinical Research and Development, Alexandra Mancini, Senior Vice President, Clinical and Regulatory Affairs, and Michael Woodenberg, Vice President of Chemistry, Manufacturing, and Control. Please be advised that certain statements in the following conference call regarding expectations for InMed's business operations, clinical development, key personnel, contractual arrangements, regulatory approvals, revenue opportunities, and cash runaway all constitute forward-looking statements. Such statements are not historical facts, but rather predictions about the future, which inherently involve assumptions, risks, and uncertainties. Actual results may differ materially from those contained in the forward-looking statements. A description of these risks can be found in our latest disclosure documents and recent press releases. Should there be any discrepancy between any statements made during this teleconference and our filed financial statements, the listener is instructed to rely on the filed financial statements for accuracy. INMED does not undertake any obligation to update any forward-looking statements made during this call And with that, I'd now like to turn the call over to InMed's President and CEO, Eric Adams. Eric.
Thank you, Bruce, and thank you, everyone, for joining us today. Since our last earnings call with investors, InMed's efforts have been focused on our core R&D programs where we've made measurable strides and hit important milestones in the last few months. We believe these important milestones bring us a step closer to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. We are pleased with the progress, and I'd like to go through the specifics of our programs with you. I'm going to start with INM 755 for epidermolysis bullosa, or EB. During the last few months, our clinical team has invested a tremendous amount of effort in preparation and coordination of the necessary Components to file and initiate our first phase two trial designated 755-201-EB, or I'll refer to it also as the 201 trial, to test the safety and efficacy of INM-755 cannabinol cream in persons with EB. On April 28th, we announced that clinical trial applications were filed in Austria, Israel, and Serbia. Since then, additional submissions for our 201 trial were made in France and Germany. We also expect to file clinical trial applications with the national competent authorities and ethics committees in Greece and Italy over the next few weeks. Responses from these authorities are expected throughout July and August, with timing to vary slightly country to country due to differences in local procedures. Filing clinical trial applications in these countries to the national competent authorities, or NCA's, serve the same purpose as filing an Investigational New Drug Application, or IND, to the US FDA. The NCAs review the dossier that summarizes all non-clinical and clinical studies conducted to date, as well as quality data regarding the manufacturing of the sterile INM-755 cream in the context of the proposed study. The ethics committees fulfill the same role as institutional review boards or IRBs in the U.S., focusing primarily on the study protocol, the investigator's brochure, and informed consent documents to assess the ethical and safety aspects of the proposed study. The 201 trial is designed to enroll up to 20 patients conservatively within 10 to 12 months and will take place at 10 pre-qualified clinical sites in the aforementioned countries. All four types of inherited EB, including EB simplex, dystrophic EB, junctional EB, and Kindler syndrome, are eligible for the study, in which NMED will evaluate the safety of INM755 cannabinol cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day period. The study will use a within-patient, double-blind design where matched index areas will be randomized to INM755 cannabinol cream or vehicle cream as a control. With these submissions in place and the expected subsequent approvals, our Phase II trial is on track to begin in the third quarter of calendar 2021. The start of the 201 trial will mark an important milestone. as the first time a cannabinol product will be entering a Phase II efficacy clinical trial for potential therapeutic use. This is a significant step for the use of a rare cannabinoid and may offer hope to patients who are seeking alternative treatment options for their disease. I'd now like to discuss our advances with the Integrison platform. Integrison is a manufacturing approach that utilizes an enzymatic biotransformation process as part of an overall integrated manufacturing approach to overcome certain natural yield limitations of traditional biosynthesis for full cannabinoid assembly. Our Integrison program achieved an important milestone over the last few weeks. On April 26, we announced that InMed's Integrison manufacturing approach was able to achieve a level of 2 grams per liter cannabinoid yield, a milestone that signals commercial viability and supports advancement to large-scale production in the coming months. Our goal with Integrison is to bring a cost-effective solution to pharmaceutical-grade rare cannabinoid production. We had set two main objectives in our development process. That was to achieve a commercially viable yield higher than current industry standards and to lower overall manufacturing costs through process optimization. Thus far, we were able to achieve both objectives. Having achieved a two gram per liter yield level, InMed will now focus on manufacturing scale up to larger batch sizes while continuing process and enzyme optimization targeted to increase cannabinoid yield and further reduce the overall cost of goods. In parallel, the company continues to prepare the manufacturing process to be GMP ready for pharmaceutical grade production. As we scale up, we believe there is additional opportunity to reach higher yield and further optimize the process to reduce overall costs. The next stage of large-scale production is to produce a batch with a target output of one kilogram of a selected cannabinoid in the second half of 2021 using a GMP-ready process. Achieving the one-kilogram batch size is important. The process parameters used at this scale are applicable to all subsequent scale-up activities. Now I'd like to turn to our INM088 program in glaucoma. INM088 is a topical eyedrop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient in 088 is cannabinol, or CBN, the same active ingredient as the 755 program. Chlorid glaucoma treatments work to reduce the intraocular pressure in the eye. Our preclinical studies have indicated that 088 may provide neural protection as well as reducing intraocular pressure. In our 088 program, over the last few months, we've engaged a leading ocular clinical research organization to develop our clinical trial program. And we've also started to scale up the 088 drug product using the MyDrops iDrop delivery technology, which we licensed from the company ICRO late last year. We have submitted our key preclinical data on the 088 program to a peer-reviewed journal and look forward to sharing our data with everyone in the not-too-distant future. The editorial process is unique to each journal, and it's difficult for us to predict when the publication will occur. Over the next several months, we expect to conduct non-GLP dose-ranging studies, followed by the GLP toxicology studies to enable human clinical trials. Our current estimates are to file applications in the first half of 2022 to initiate human clinical testing with INM088. In terms of other activities, I'd like to provide an update on our BayMedica collaboration. BayMedica is continuing its experimentation using one of NMED's enzyme gene sequences in their yeast-based biosynthesis system. Early data indicate that the enzyme is active in the system, but further optimization is required. With regards to NMED's testing of BayMedica's cannabinoid analog compounds, we have recently received the permit from Health Canada to import these analogs. The process was expected to take six weeks, but was significantly delayed as we waited for Health Canada's approval. We will import these compounds and initiate our preclinical testing ASAP. We believe the synergy of this collaboration will give us important knowledge in furthering the development of our Integrison approach and the compounds it may be able to cost-effectively produce. It also provides us with the know-how for production of cannabinoids we intend to use for our own therapeutic programs. Over the last quarter, we increased our business development activities. We believe business development is an important avenue to help accelerate our company and R&D programs. We will continue to explore options that will add value to InMed and will extend our lead in the clinical development of cannabinol and our cannabinoid manufacturing. Finally, on April 27th, we announced that we would be voluntarily delisting from the Toronto Stock Exchange. In that approximately 86% of our trading volume occurred on the NASDAQ, the lower trading volume on the TSX no longer justified the expense and administrative efforts associated with maintaining a dual listing. As planned, the voluntary delisting occurred on May 7th. Our shares continued to be listed and traded on the NASDAQ under the symbol INM. The substantial savings in exchange fees, legal fees, and managerial time and effort can now be redirected into our scientific programs, further advancing the business of the company. With that, I'd like to turn the call over to Bruce to discuss our financials. Bruce?
You're reading a preview of the INM Q3 2021 earnings call.
Free account.
